IntegraGen appoints Gerald Wagner to the Board of Directors

Paris, France; 6 April 2005 ….. IntegraGen, the personalized medicines company, announced today that it has appointed Gerald Wagner as non-executive director. Gerald brings over 30 years of commercial experience to IntegraGen, having held a number of senior roles at Agfa Corporation and Bayer Corporation during his career.

Dr Jan Mous, CEO of IntegraGen said:
“We are very pleased to welcome Gerald to IntegraGen’s board. His outstanding experience in the operational and strategic aspects of the diagnostics business will be of particular relevance to IntegraGen, as we expand our genetic diagnostics business and bring ground breaking genetic tests for autism and diabetes to market.”

Gerald started his commercial career at Agfa-Gevaert, Munich, having obtained a PhD from the Technical University in Darmstadt, Germany, rising through the ranks to be President of Agfa Matrix Division at Agfa Corporation, USA and elected to the Agfa-Gevaert, Inc board. He then joined the Diagnostic Systems Business Group of Bayer Corporation as Senior Vice-President leading, the worldwide Laboratory Testing Segment. On retiring from Bayer, he transferred his experience to the Company by developing a 15 year strategy for the diagnostics group. Since leaving Bayer in 2002, Gerald has had great success as a consultant to a number of companies and organizations, providing international project management, automation and materials management, and long-term strategy expertise.

Dr Wagner commented:
“I am looking forward to working with the exceptional team in IntegraGen to introduce and progress the tests to market. I am convinced that they will reduce healthcare costs and, most importantly, improve patient’s lives.”

IntegraGen is developing informative and predictive genetic tests for several common diseases. It is applying its expertise in genetic analysis and unique GenomeHIP^® technology to identify genes associated with complex diseases. This information will then be translated into the development and commercialization of clinically informative genetic tests to support personal health management decisions. The Company plans to have its first in-house developed genetic test for autism on the market in 2006 and anticipates providing a genetic test for type 2 diabetes in 2007.

- ENDS -

About IntegraGen

IntegraGen SA uses its unique genomic analysis expertise to identify genes associated with complex diseases and to develop diagnostic and predictive genetic tests. The Company applies its innovative gene mapping technology, GenomeHIP® (Genome Hybrid Identity Profiling), to rapidly discover genetic loci that are implicated in complex, multi-factorial diseases. GenomeHIP® is a major advance that overcomes the limitations of existing marker based familial linkage study methods.

IntegraGen is applying its discoveries to develop a series of innovative IntegraTests™ and is poised to become a leader in the rapidly growing field of predictive medicine. The Company will be a fully integrated provider of genetic tests that can be used to predict, prevent, diagnose and tailor personalized treatments for complex diseases. Testing will be provided as a service through Expert Centers, which will also provide expert analysis and genetic counseling from an accredited MD-geneticist. The Company’s first Expert Center has been established in Bonn, Germany, to provide the Company’s first testing service for MODY diabetes (Mature Onset Diabetes of the Young) testing. The Bonn center will become fully operational in April this year.

The Company's strategy is to develop molecular diagnostic tools for selected disease areas with high medical need. IntegraGen's in-house programs are focused on neurological disorders, including autism and bi-polar disorder, and metabolic disorders, such as obesity and type 2 diabetes mellitus. The IntegraTest for autism, the world’s first genetic test for autism, is currently in the clinical validation phase of development, with an anticipated launch in 2006. The Company’s IntegraTest for type-2 diabetes is expected to enter clinical validation in 2006.

Founded in July 2000, IntegraGen has 34 employees and is based in the French Genopole of Evry, near Paris, France, and in Bonn, Germany.

More information can be found at www.integragen.com

Media enquiries

Northbank Communications

Rebecca Todd, Senior Account Manager

Tel: +44 (0)20 7886 8157

Mobile: +44 (0)7801 573073

E-mail: r.todd@northbankcommunications.com

Sue Charles, CEO

Tel: +44 (0)20 7886 8152

Mobile: +44 (0)7968 726585

E-mail: s.charles@northbankcommunications.com

At IntegraGen SA, Paris

Dr Jan Mous, CEO

Tel: +33 (0)1 60 91 09 00

Email: jan.mous@integragen.com